ClinicalTrials.gg

Program

glecirasib

Also written as “JAB-21822”, “JAB-21822 (KRAS G12C inhibitor)” and “Glecirasib”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Appendiceal Neoplasms · Pancreatic Neoplasms, led by 4 companies.

Furthest: phase 3, since May 9, 202412 company-led studies, 8 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Allist Pharmaceuticals96 open or runningphase 3since May 9, 2024Jul 26, 2021Dec 31, 2026phase 2 · NCT06008288
Abbisko Cayman11 open or runningphase 2since Sep 2, 2025Sep 2, 2025Dec 30, 2028phase 2 · NCT07164170
Jacobio Pharmaceuticals10 open or runningphase 2since Jul 26, 2021Jul 26, 2021none ahead
Sichuan Biokin Pharmaceutical11 open or runningphase 2since Sep 14, 2026Sep 14, 2026Dec 2028phase 2 · NCT07827261

Also a collaborator on its studies: baili-bio-chengdu-pharmaceutical-co-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 26, 2021First study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Allist PharmaceuticalsAllist Pharmaceuticals · NCT05009329 · 315 enrolled · China
  2. Jul 26, 2021First study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Jacobio PharmaceuticalsJacobio Pharmaceuticals · NCT05002270 · 29 enrolled · United States
  3. Dec 27, 2021Phase 2 study in Appendiceal NeoplasmsAllist Pharmaceuticals · NCT05194995 · 48 enrolled · China
  4. Mar 3, 20222 phase 2 studies in Carcinoma, Non-Small-Cell LungAllist Pharmaceuticals · NCT05276726, NCT05288205
  5. Apr 23, 2023Phase 1 study in Food Effect in Healthy ParticipantsAllist Pharmaceuticals · NCT05875493 · 18 enrolled · China
  6. Jun 6, 2023Phase 1 study in Mass Balance Study in Healthy SubjectsAllist Pharmaceuticals · NCT05920941 · 6 enrolled · China
  7. Aug 18, 2023Phase 2 study in Pancreatic NeoplasmsAllist Pharmaceuticals · NCT06008288 · 88 planned · China
  8. Nov 29, 2023Phase 1 study in Healthy SubjectsAllist Pharmaceuticals · NCT06162169 · 66 enrolled · China
  9. May 9, 2024Phase 3 study in Advanced Non-squamous Non-small-cell Lung CancerAllist Pharmaceuticals · NCT06416410 · 392 planned · China
  10. Sep 2, 2025Abbisko Cayman's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Abbisko CaymanAbbisko Cayman · NCT07164170 · 86 planned · China
  11. Sep 14, 2026Sichuan Biokin Pharmaceutical's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Sichuan Biokin PharmaceuticalSichuan Biokin Pharmaceutical · NCT07827261 · 36 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in Pancreatic NeoplasmsAllist Pharmaceuticals · NCT06008288
  2. Mar 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungAllist Pharmaceuticals · NCT05288205
  3. Aug 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungAllist Pharmaceuticals · NCT05276726
  4. Dec 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungSichuan Biokin Pharmaceutical · NCT07827261

TargetBeta

KRAS →read by rule
“An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, ”NCIt, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36
opnurasibruleNovartisphase 35

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07827261Carcinoma, Non-Small-Cell Lung · China2Not yet recruitingSichuan Biokin PharmaceuticalDec 202836
NCT07164170Carcinoma, Non-Small-Cell Lung · China2RecruitingAbbisko CaymanDec 30, 202886
NCT06416410Advanced Non-squamous Non-small-cell Lung Cancer · China3RecruitingAllist PharmaceuticalsSep 30, 2029392
NCT06162169Healthy Subjects · China1CompletedAllist PharmaceuticalsFeb 20, 202466
NCT06008288Pancreatic Neoplasms · China2RecruitingAllist PharmaceuticalsDec 31, 202688
NCT05920941Mass Balance Study in Healthy Subjects · China1CompletedAllist PharmaceuticalsAug 9, 20236
NCT05875493Food Effect in Healthy Participants · China1CompletedAllist PharmaceuticalsJun 14, 202318
NCT05288205Carcinoma, Non-Small-Cell Lung · China2RecruitingAllist PharmaceuticalsMar 2027240
NCT05276726Carcinoma, Non-Small-Cell Lung · China2RecruitingAllist PharmaceuticalsAug 2027104
NCT05194995Appendiceal Neoplasms · China2Active, not recruitingAllist PharmaceuticalsApr 30, 202548
NCT05009329Carcinoma, Non-Small-Cell Lung · China2Active, not recruitingAllist PharmaceuticalsAug 2026315
NCT05002270Carcinoma, Non-Small-Cell Lung · United States2CompletedJacobio PharmaceuticalsFeb 12, 202529

How it is read

Names in the registry

  • “JAB-21822”, 10 entries
  • “JAB-21822 (KRAS G12C inhibitor)”, 3 entries
  • “Glecirasib”, 1 entry
  • “JAB 21822”, 1 entry
  • “ABSK043 in combination with Glecirasib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.